Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 13/20 | 0.80 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.80 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.80 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.60 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL11563214 | 0.94 | OPRM1 (0.72) | OPRM1OPRD1OPRK1CACNA1COPRL1 | |
| SCHEMBL821488 | 0.92 | OPRM1 (0.78) | OPRM1OPRD1OPRK1CACNA1COPRL1 | |
| SCHEMBL11569033 | 0.92 | OPRM1 (0.78) | OPRM1OPRD1OPRK1CACNA1COPRL1 | |
| Hydrochloric Acid SCHEMBL11565387 | 0.91 | OPRM1 (0.68) | OPRM1OPRD1OPRK1 | |
| SCHEMBL14530925 | 0.91 | OPRM1 (0.77) | OPRM1OPRD1OPRK1CACNA1COPRL1 | |
| Oxalic Acid SCHEMBL11567140 | 0.89 | OPRM1 (0.65) | OPRM1OPRD1OPRK1CACNA1C | |
| Carfentanil SCHEMBL116222 | 0.89 | OPRM1 (1.00) | OPRM1OPRD1OPRK1CACNA1COPRL1 | |
| [11C]-Carfentanil SCHEMBL29374424 | 0.89 | OPRM1 (1.00) | OPRM1OPRD1OPRK1CACNA1COPRL1 | |
| SCHEMBL6045452 | 0.88 | OPRM1 (0.62) | OPRM1OPRD1OPRK1CACNA1C | |
| Carfentanil SCHEMBL238456 | 0.88 | OPRM1 (0.98) | OPRM1OPRD1OPRK1CACNA1COPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987501-B2 | Isotopically labeled chemically stable reagents and process for the synthesis thereof | PERKINELMER HEALTH SCIENCES, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20100099880-A1 | Alternate Process for Remifentanil Preparation | MALLINCKRODT INC. | 2010-04-22 | — | — | US | disclosed |
| EP-2125730-A2 | NEW PROCESS FOR REMIFENTANIL SYNTHESIS | Mallinckrodt Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| EP-2081899-A2 | ALTERNATE PROCESS FOR REMIFENTANIL PREPARATION | Mallinckrodt Inc. (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20080319196-A1 | Process for Synthesizing Remifentanil | MALLINCKRODT INC. | 2008-12-25 | — | — | US | disclosed |
| US-20080312448-A1 | Process for Synthesizing Remifentanil | MALLINCKRODT INC. | 2008-12-18 | — | — | US | disclosed |
| EP-1984336-A2 | PROCESS FOR SYNTHESIZING REMIFENTANIL | MALLINCKRODT, INC. (US) | 2008-10-29 | — | — | EP | disclosed |
| EP-1966140-A1 | PROCESS FOR SYNTHESIZING REMIFENTANIL | MALLINCKRODT, INC. (US) | 2008-09-10 | — | — | EP | disclosed |
| WO-2008066708-A2 | NEW PROCESS FOR REMIFENTANIL SYNTHESIS | MALLINCKRODT INC. (US) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008045192-A2 | ALTERNATE PROCESS FOR REMIFENTANIL PREPARATION | MALLINCKRODT INC. (US) | 2008-04-17 | — | — | WO | disclosed |
| WO-2007087164-A2 | PROCESS FOR SYNTHESIZING REMIFENTANIL | MALLINCKRODT INC. (US) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007061555-A1 | PROCESS FOR SYNTHESIZING REMIFENTANIL | MALLINCKRODT INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-5843900-A | Bradykinin antagonists | CORTECH, INC. (US) | 1998-12-01 | — | — | US | disclosed |
| EP-0832106-A2 | COMPOUNDS HAVING BRADYKININ ANTAGONISTIC ACTIVITY AND MU-OPIOID AGONISTIC ACTIVITY | CORTECH, INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996039425-A2 | COMPOUNDS HAVING BRADYKININ ANTAGONISTIC ACTIVITY AND MU-OPIOID AGONISTIC ACTIVITY | CORTECH, INC. (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319196-A1 | Process for Synthesizing Remifentanil | OPRK1, OPRM1, OGFR | OPRM1 2/4885OPRD1 5/4885OPRK1 1/4885 |
| US-20100099880-A1 | Alternate Process for Remifentanil Preparation | OPRK1, OPRM1, OGFR | OPRM1 2/4885OPRD1 5/4885OPRK1 1/4885 |
| US-20080312448-A1 | Process for Synthesizing Remifentanil | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885OPRD1 3/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.